Dolutegravir plus lamivudine shows comparable efficacy and safety with standard-of-care three-drug regimen in patients with ...

Switching to islatravir and doravirine was just as effective as bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

Seven weeks into US President Donald Trump’s suspension of foreign aid, including funds for HIV/ AIDS treatment, panic has gripped persons living with the virus as they cannot access the required ...

Data from two studies suggest that a once-daily combination therapy of doravirine and islatravir was noninferior to current, ...

“I’m excited to see that DOR/ISL has potential as a new daily treatment option for people living with HIV who may benefit from this two-drug regimen.” Islatravir, Merck’s investigational ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

A double-blind study investigated the therapy in adult patients with HIV-1 infection suppressed ... “We are excited that DOR/ISL is the first two-drug regimen without an integrase inhibitor ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Two clinical trials presented last week at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco show that a two-drug regimen of doravirine / islatravir is ...

The HIV drugs industry consists of antiretroviral ... With the introduction of once-daily regimens, fixed-dose combinations, and long-acting injectable therapies, the industry is witnessing ...